Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA To Publish Own Datasets In Latest Signal Of Enhanced Transparency

Executive Summary

Adverse event reporting data will also be more readily available, Commissioner Scott Gottlieb says.

You may also be interested in...



Gottlieb Issues Statement On Adverse Event Limitations – An Attempt To Quell Fears?

Commissioner Scott Gottlieb's statement noting the limitations of FAERS comes just four days after he was quoted in an FDA announcement about the launch of a more searchable portal for the adverse event database.

Gottlieb's Tweets: Skirting The Rules Or Advancing Policy?

The current FDA commissioner discussed use of the social media platform with his predecessor Robert Califf at a meeting on real-world evidence.

Alzheimer's Guidance Coming From US FDA, Part Of Broader OND Reform

'Believe it or not, we don't have as many disease-specific guidances as you would suspect on the new drug side,' Commissioner Gottlieb says.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS121575

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel